DALLAS, July 27, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring biopharmaceutical company Onyx Pharmaceuticals Inc. (Nasdaq:ONXX). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Onyx Pharmaceuticals Inc. (Nasdaq:ONXX) should be of particular interest to other drug developers: Pfizer Inc. (NYSE:PFE), OSI Pharmaceuticals Inc. (Nasdaq:OSIP), Amgen Inc. (Nasdaq:AMGN) and Seattle Genetics Inc. (Nasdaq:SGEN).
It is available at: http://www.stockpreacher.com/n/ONXX
Onyx Pharmaceuticals Inc. (ONXX) is a biopharmaceutical company engaged in developing therapies that target the molecular mechanisms that cause cancer. The Company's product, Nexavar (sorafenib) tablets, being developed with the Company's collaborator Bayer HealthCare Pharmaceuticals (Bayer), is approved by the United States Food and Drug Administration (FDA), for advanced kidney cancer and liver cancer. Nexavar is an orally available kinase and angiogenesis inhibitor and is one of a new class of anticancer treatments that target both cancer cell proliferation and tumor growth through the inhibition of key signaling pathways.
In the report, the analyst notes:
"ONXX's continued profitability has reportedly been driven by Nexavar's sales. Global Nexavar net sales were $178.1 million for the first quarter 2009, a 17% increase compared to $151.9 million in the same period in 2008.
"The Company remains focused on maximizing opportunities ahead, supporting important new Nexavar clinical trials. ... On July 22, ONXX shares rose almost 25% at $35.78 after the Company and collaborator Bayer reported that a phase II study of Nexavar showed the product could help slow the progression of advanced breast cancer when used in conjunction with a leading chemotherapy agent, capecitabine."
To read the entire report visit: http://www.stockpreacher.com/n/ONXX
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.
CONTACT: StockPreacher.com
Jeff Bishop
(469)-252-3505
press@beaconequity.com
